Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Anaqua Announces Executive Leadership Changes in the Asia-Pacific Region

Shinji Tokunaga Joins as President & General Manager, Japan

BOSTON, Sept. 05, 2022 (GLOBE NEWSWIRE) — Anaqua, the leading global innovation and intellectual property (IP) management technology provider, today announced changes to its executive leadership team in the Asia-Pacific region as it continues on its long-term growth trajectory. Shinji Tokunaga joined Anaqua effective September 1, 2022, as President & General Manager, Japan. Karen Taylor, General Manager, Asia Pacific, will be leaving the company, having led Anaqua’s growth in the region for over five years.

“I want to thank Karen for her leadership and commitment to our customers, colleagues, and stakeholders,” said Anaqua CEO Bob Romeo. “Karen has been influential in developing our business and positioning Anaqua for future growth as well as serving as a member of our global leadership team.”

Tokunaga-san most recently served as Representative Director and CEO of Global Open Network Japan, Inc., where he led the entire operation, and the development and commercialization of a new payment service platform business using blockchain technology. Prior to Global Open Network Japan, Tokunaga-san held leadership positions at Akamai Technologies, Attachmate, Novell Japan, and Borland. Tokunaga-san holds a Bachelor of Arts degree from Hosei University.

“Anaqua is an impressive company, and I am excited to join the team. Intellectual property is a critical asset for companies, and we have a great opportunity to help our clients derive more value from their portfolios,” said Tokunaga.

“We are very pleased to have someone with Tokunaga-san’s extensive experience leading the business and overseeing our next stage of growth and investment in Japan,” Romeo added. “His proven track record positions him well to lead our cross-functional teams and partner with our existing and future clients in the market. I am proud of what we have accomplished in Japan thus far and I am excited for what is yet to come.”

About Anaqua

Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX and PATTSY WAVE, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on LinkedIn.

Company Contact:
Amanda Hollis
Director, Communications
Anaqua
617-375-5808
ahollis@Anaqua.com

HTEC Group acquires Mistral Technologies to Expand its Engineering Base in Southeast Europe to Over 2,000 Professionals

SAN FRANCISCO, Sept. 02, 2022 (GLOBE NEWSWIRE) — HTEC Group (“HTEC”) (www.htecgroup.com), a global consulting, software engineering and digital product development company based in San Francisco, today announced that it has acquired Sarajevo-based Mistral Technologies. Joining forces with Mistral’s team of 300, HTEC is now the largest technology company in Bosnia and Herzegovina employing close to 600 experts in the country.

Globally, HTEC’s team has grown to over 2,000 employees, with development centers across Southeast Europe — where the company operates in six countries — with creative and consulting offices located in the Silicon Valley, London, New York, Minneapolis, Amsterdam, Stockholm and Gothenburg. By combining Silicon Valley-based design thinking with the best of SEE engineering talent in more than 20 locations, HTEC supports global clients with digital product development, from strategy and conceptualization to design and agile engineering on scale.

Mistral, the newest member of HTEC Group, was founded in Sarajevo in 2010, and has positioned itself as the employer of choice for engineering talent in Bosnia and Herzegovina, an impressive client portfolio of Fortune 500 companies.

“Building strong relationships based on trust, delivering excellence and creating additional value for our prized client partnerships has always been at the forefront of our strategy alongside providing a people centric work environment. We are perfectly aligned with HTEC Group in terms of our values and service delivery and I am confident we will soon become the most desired partner of choice globally, for the most complex engineering challenges,” commented Mersed Camdzic, Mistral co-founder and CEO.

“I am happy to say that today we acquired Mistral Technologies, one of the best technology companies in the region, clearly a market leader in Bosnia and Herzegovina, with the passion, leadership skills, engineering excellence and company values that match our own. Going forward, we will continue to bring together by far the most talented technical and creative professionals in Southeast Europe and expose them to global market opportunities,” said Aleksandar Cabrilo, HTEC co-founder and CEO.

Expereo appoints new General Counsel and SVP of Enterprise Sales as part of continued investment strategy

AMSTERDAM, Aug. 31, 2022 (GLOBE NEWSWIRE) — The world’s leading provider of managed network solutions, Expereo welcomes Sujata Kukreja, General Counsel and Scott Zarriello, SVP Enterprise Sales into its ranks. Both recent appointments come as part of a continued global investment strategy to further tailor solutions and experiences to all regions based on customer demand, while maintaining the same best-in-class service around the world.

“Expereo’s steep growth trajectory has been fueled by a great influx of talent. I am thrilled to announce the expansion of the leadership team with the addition of Sujata and Scott, who will be instrumental in creating seamless customer solutions globally. Scott adds his experience and talent to our dynamic sales leadership team. In his role as our new Senior Vice President of Enterprise Sales, Americas, he will further develop the potential of the American market,” commented Irwin Fouwels, Chief Executive Officer of Expereo.

Sujata Kukreja joins Expereo from Knauf where she was spearheading operations in the APAC region, managing legal and ESG compliance, governance, and risk management. Her wealth of experience in providing practical and innovative regulatory solutions on a global level will be critical in Expereo’s ongoing expansion and international business operations.

“I am passionate about ensuring businesses grow and develop in an ethical and sustainable manner. I am excited to utilize my expertise in my new role and be part of Expereo’s continued success story,” says Sujata Kukreja, new General Counsel of Expereo.

Scott Zarriello joins Expereo from Vodafone where he held the position of VP of Global Sales and US Operations, leading the senior strategic sales team for outsourcing and managed services. His experience of over 30 years within the Technology and Telecommunications industries will be instrumental in aligning Expereo’s global sales strategy while tailoring solutions and service offerings to the regional customer needs.

“Delivering the results our customers need to grow and thrive is my number one priority. I am incredibly excited to join the team at Expereo and continue building on the company’s expertise in connectivity on a global scale with innovative solutions,” commented Scott Zarriello, new SVP of Enterprise Sales at Expereo.

About Expereo
Expereo is a leading global provider of managed network solutions including, Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 30% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, helping customers improve productivity and empowering their networks and cloud services with the agility, flexibility and value of the Internet, with optimal network performance.

Expereo was acquired in Feb 2021, by Vitruvian Partners. The international growth capital and buyout firm acquired a majority shareholding from leading European private equity firm, Apax Partners sas.

For more information visit: www.expereo.com.

Emese Csikai
Senior Account Executive
emese@grammatikagency.com

EMGA advises on US$10M debt raise for Banco D-Miro

LONDON, Aug. 31, 2022 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory Limited (EMGA), the niche investment bank focused on emerging markets, announces a Senior Debt raise transaction in Ecuador that will allow Banco D-Miro to continue the expansion of its microcredit lending activities in Ecuador.

The US$10 million debt facility was originated, advised upon, and structured by EMGA with financing provided by U.S. International Development Finance Corporation (DFC) and the transaction is the first time EMGA has completed an operation in Ecuador.

Commenting on the transaction, Banco D-Miro’s CFO Fabian Victores Baque said, “We appreciate the support of EMGA and DFC to finalize this important transaction. Having a strategic partner such as DFC will help us to meet our objectives of generating more financial inclusion and increasing financing to women microentrepreneurs.”

Jim Polan, Vice President of DFC’s Office of Development Credit, said, “DFC’s investment in Banco D-Miro will expand access to financing, enabling low-income populations and women entrepreneurs in Ecuador to recover from the COVID-19 economic downturn. With a focus on small businesses, this transaction will advance long-term development and economic growth in Ecuador, a key goal for DFC.”

Sajeev ChakkalakalManaging Director and Head of Investment Banking at EMGA, said, “It was a real pleasure for EMGA to have advised Banco D-Miro on this important transaction aimed at funding their small and medium enterprise loan portfolio with a particular focus on women-owned enterprises. Furthermore, closing yet another transaction with DFC demonstrates the strength of our relationship built across several years. Finally, we believe DFC’s position as a pre-eminent development finance institution will add a new, strategic long term funding source for Banco D-Miro.”

Jeremy DobsonManaging Director of EMGA, added, “With this first transaction in Ecuador, EMGA adds to its operational footprint in Latin America, and we will continue to develop business in the country and the region.”

Banco D-Miro: Banco D-Miro is an Ecuadorian bank specialized in microfinance and their vision is to be the bank that contributes the most to the reduction of poverty. The bank offers financial services to the micro, small and medium entrepreneurs in Ecuador and especially those areas, where the poverty levels are higher, and the penetration of financial services is the lowest.

DFC: U.S. International Development Finance Corporation (DFC) partners with the private sector to provide financing solutions that aim to address the problems facing the developing world. We invest across sectors including energy, healthcare, critical infrastructure, and technology. DFC also provides financing for small businesses and women entrepreneurs in order to create jobs in emerging markets. DFC investments adhere to high standards and respect the environment, human rights, and worker rights.

Emerging Markets Global Advisory LLP, based in London, helps financial institutions and corporations seeking debt/equity capital. EMGA’s team combines the decades of experience needed to complete transactions in emerging countries including Ecuador, which remains a key market. EMGA continues expanding and solidifying its place as a niche investment bank focused on emerging markets.

Jeremy Dobson

info@emergingmarketsglobaladvisory.com

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

  • Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy

SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study 1 that shows the EndoPredict® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer. This newly published study represents the first clinical validation of EndoPredict in a solely premenopausal population.

The study — first presented in an abstract at the 2021 ASCO Annual Meeting by Anastasia Constantinidou et al2 — examined tumor samples from 385 premenopausal women with ER+, HER2- primary breast cancer who had not received chemotherapy. The results show EndoPredict accurately identified premenopausal women with and without affected lymph nodes who could safely avoid adjuvant chemotherapy as part of their treatment plans due to a very low recurrence risk.

“This important publication on the new EndoPredict data demonstrates our ongoing commitment to advance precision medicine for patients with breast cancer,” said Dr. Ralf Kronenwett, director of International Medical Affairs, Myriad Genetics. “In light of mounting clinical recommendations to reduce overtreatment in breast cancer, the results are particularly encouraging. With around a third of all new breast cancer cases occurring in patients aged 54 or younger3, using EndoPredict among premenopausal women provides important insights to inform personalized treatment, including whether there’s a benefit to using chemotherapy or not.”

The study shows that patients with EndoPredict low-risk scores had a 97% distant recurrence free survival (DRFS) versus 76% for high-risk patients. Importantly, 19% of node-positive premenopausal patients had EndoPredict low-risk scores with 100% DRFS and were able to safely avoid chemotherapy and continue onto endocrine therapy alone.

Another key result from an exploratory subgroup analysis within the study found similar DRFS rates in low-risk patients with or without ovarian function suppression (OFS), with less than 5% distant recurrence after 10 years in both groups.

“This important study shows that premenopausal patients with a low-risk EndoPredict score have a good long-term outcome without chemotherapy and may be considered for treatment with endocrine therapy only,” said Dr. Anastasia Constantinidou, Bank of Cyprus Oncology Centre and Cyprus Cancer Research Institute. “These findings are relevant to better inform personalized treatment decisions for a large proportion of premenopausal women with ER+, HER2- early-stage breast cancer.”

About the study
EndoPredict is a prognostic test that predicts patient risk of breast cancer recurrence to help identify who can consider safely forgoing chemotherapy. It analyzes 12 genes to create a molecular score, which is combined with tumor features, such as tumor size and nodal status, to establish a patient risk score (EPclin).

The Clinical Validation of EndoPredict in Premenopausal Women study tested tumor samples from 385 premenopausal women with ER+, HER2- primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy. All samples were retrospectively tested blinded to clinical and outcome data with EndoPredict. Associations of EPclin Risk Scores with 10-year DRFS were evaluated by Cox proportional hazards models and Kaplan-Meier analysis. The primary outcome was 10-year DRFS.

In addition to EPclin, clinical variables of interest included age at diagnosis, tumor size, tumor grade, nodal status, Ki 67 expression, and continuous estrogen receptor (ER) expression and progesterone receptor (PgR) expression.

More information about this study can be found here.

1 Constantinidou et al. Clin Cancer Res 2022 (https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-0619/708058/Clinical-Validation-of-EndoPredict-in)
2 Constantinidou et al 2021 ASCO (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.537)
3 SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute;2019.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to using EndoPredict among premenopausal women to provide important insights to inform personalized treatment, including whether there’s a benefit to using chemotherapy or not. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com
Investor Contact:
Foster Harris
(385) 350-8015
Foster.Harris@myriad.com

Copenhagen Infrastructure Partners reach final close on CI Energy Transition Fund I at the EUR 3 billion hard cap

COPENHAGEN, Denmark, Aug. 31, 2022 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners (CIP) has reached final close on its new fund, CI Energy Transition Fund I (CI ETF I). The fund was oversubscribed and closed at the hard cap of EUR 3 billion. This makes CI ETF I the largest dedicated clean hydrogen fund globally.

CI ETF I achieved commitments from investors across the Nordics (~25% of commitments), Europe (~45%), Asia-Pacific (~20%) and North America (~10%) with approximately a 50/50 split between existing investors in CIP funds and new investors. The fund’s investor base comprises approximately 65 institutional investors, primarily pension funds, life insurance companies, sovereign wealth funds, asset managers, and family offices.

“We are very pleased to welcome a prominent group of existing and new institutional investors to CI ETF I and are delighted that investors share our confidence in and appetite for clean energy infrastructure projects and invest alongside CIP in the next phase of the energy transition. Solutions such as Power-to-X will be key for countries and industries to take the next big leap within reaching the commitments of the Paris agreement and achieving energy independence. As an industry pioneer and one of the global market leaders in greenfield renewable infrastructure investments, CIP is uniquely positioned to invest in this segment,” says Jakob Baruël Poulsen, Managing Partner in CIP.

CI ETF I will invest in next generation renewable energy infrastructure including industrial scale Power-to-X (PtX) projects and enables institutional investors to participate in the decarbonization of the so-called hard to abate industries and support the further integration of renewable power generation in the energy mix through grid balancing. The fund will primarily focus on greenfield projects in the OECD and aims to contribute to the decarbonization of industries such as agriculture, aviation, shipping, chemical manufacturing, and steel production through the use of green fuels and feedstock and CO2-free fertilizers.

CI ETF I make up an integral part of CIP’s distinct fund strategies that tap into the main renewable energy transition trends. The fund will apply the same and proven value creation and de-risking approach as CIP’s existing funds, though with a focus for CI ETF on PtX. CI ETF I will apply CIP’s industrial skills to optimize and de-risk its projects through among others project design, partner selection, and contracting. Once de-risked the projects are expected to have core infrastructure characteristics including long term offtake contracts.

CI ETF I is off to a strong start with FID taken on one investment and ownership on several attractive industrial scale development stage PtX projects with diverse exposure to production technologies and offtake markets. The projects which among others are in Western Europe (Denmark, Norway, Spain, Portugal), South America (Chile), and Australia are expected to produce green hydrogen, green ammonia, and sustainable aviation fuel based on GW scale renewable energy production and electrolysis capacity.

CI ETF I’s current portfolio once operational is estimated to reduce more than 7.5 million tonnes of CO2 annually (or the equivalent to removing ~1.6 million cars from the roads permanently) and deliver more than 4 million tonnes of green fuels each year.

For the marketing of CI ETF I, law firms Plesner and Clifford Chance acted as legal counsel, KPMG Acor Tax as tax advisor, and Selinus Capital Advisors, Compagnie Financière Jacques Coeur (CFJC) and Allen Partners as placement agents.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages ten funds and has to date raised approximately EUR 19 billion for investments in energy and associated infrastructure from more than 135 international institutional investors. CIP will accelerate its role in the global energy transition and aim to have EUR 100 billion under management in green energy investments in 2030. CIP has approximately 340 employees and offices in Copenhagen, London, Hamburg, Utrecht, New York, Tokyo, Singapore, Seoul, and Melbourne. For more information, visit www.cip.dk

For further information, please contact:

Simon Augustesen, – VP, Chief Communication and Marketing Officer, Phone: +45 30526721, Email: siau@cip.dk

Thomas Kønig, Partner – Investor Relations, Phone: +45 7070 5151, Email: tkon@cip.dk